Baldwin Investment Management LLC Has $1.86 Million Holdings in Zoetis Inc (ZTS)

Baldwin Investment Management LLC trimmed its stake in Zoetis Inc (NYSE:ZTS) by 8.9% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,318 shares of the company’s stock after selling 2,170 shares during the period. Zoetis comprises approximately 0.7% of Baldwin Investment Management LLC’s investment portfolio, making the stock its 13th biggest position. Baldwin Investment Management LLC’s holdings in Zoetis were worth $1,864,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ZTS. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Zoetis during the fourth quarter valued at $108,000. We Are One Seven LLC bought a new stake in Zoetis during the fourth quarter valued at $120,000. Premia Global Advisors LLC bought a new stake in Zoetis during the fourth quarter valued at $122,000. Icon Wealth Partners LLC bought a new stake in Zoetis during the fourth quarter valued at $127,000. Finally, Mckinley Capital Management LLC Delaware bought a new stake in Zoetis during the first quarter valued at $134,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Zoetis opened at $88.15 on Friday, MarketBeat.com reports. The company has a current ratio of 4.27, a quick ratio of 2.83 and a debt-to-equity ratio of 2.51. Zoetis Inc has a 1 year low of $59.50 and a 1 year high of $88.25. The stock has a market cap of $42.13 billion, a PE ratio of 36.73, a P/E/G ratio of 1.92 and a beta of 0.98.



Zoetis (NYSE:ZTS) last posted its earnings results on Wednesday, May 2nd. The company reported $0.75 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.69 by $0.06. Zoetis had a net margin of 17.97% and a return on equity of 68.51%. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.35 billion. During the same quarter in the prior year, the business posted $0.53 EPS. The firm’s revenue was up 11.0% compared to the same quarter last year. sell-side analysts expect that Zoetis Inc will post 3.06 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 4th. Investors of record on Friday, July 20th will be issued a $0.126 dividend. The ex-dividend date of this dividend is Thursday, July 19th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.57%. Zoetis’s dividend payout ratio is presently 20.83%.

In related news, insider Kristin C. Peck sold 4,877 shares of the company’s stock in a transaction dated Tuesday, May 1st. The shares were sold at an average price of $83.46, for a total value of $407,034.42. Following the sale, the insider now owns 42,652 shares in the company, valued at approximately $3,559,735.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.35% of the company’s stock.

ZTS has been the topic of a number of research analyst reports. Piper Jaffray Companies set a $88.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Friday, February 16th. Stifel Nicolaus reaffirmed a “buy” rating and set a $86.00 price target (up previously from $84.00) on shares of Zoetis in a research report on Friday, February 16th. Bank of America upped their price target on shares of Zoetis from $80.00 to $87.00 and gave the company a “buy” rating in a research report on Friday, February 16th. Cantor Fitzgerald set a $90.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Thursday, February 15th. Finally, Cowen set a $85.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Thursday, February 15th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $84.25.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply